Fapon Biotech Introduces World’s First COVID-19 Antibodies for Antigen Lateral Flow Testing in Differentiating Variant B.1.1.7 and Wild-Type Virus
By LabMedica International staff writers Posted on 29 Sep 2021 |
Fapon Biotech Inc. (Guangdong, China) introduced the world’s first COVID-19 antibodies for antigen lateral flow testing in differentiating variant B.1.1.7 and wild-type virus at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.
This year more than 35,000 industry leaders and professionals came together at the Georgia World Congress Center in Atlanta for AACC 2021. Fapon provides global diagnostic companies with high-performance IVD reagent raw materials, such as antigens, antibodies, and enzymes, as well as reagent solutions and innovative open instrument platforms.
At AACC 2021, Fapon introduced pioneering COVID-19 antibodies for antigen lateral flow testing to detect and differentiate COVID-19 and the most notable variant B.1.1.7 (also known as SARS-CoV-2 VUI 202012/01) in human samples. Variant strain surveillance is vital for COVID-19 control. Variants such as B.1.1.7 that causes 40-70% higher transmissibility and false-negative results on some PCR tests had drawn concerns and investigation from scientists and healthcare authorities like WHO, FDA and others.
The innovative COVID-19 Variant B.1.1.7 POCT Solution consists of a monoclonal antibody pair to differentiate the SARS-CoV-2 wild-type strain and the B.1.1.7 variant strain N protein. The antibody pair uses two different antibodies for immunoassay of test samples. These antibody pairs can detect B.1.1.7 and B.1.351 variants while having a consistent reaction to the wild-type virus. With the advantages of rapidity, low cost and high efficiency, this product can ensure the rapid and accurate detection of the B.1.1.7 variant strain.
Fapon also showcased its One-Stop Solution for COVID-19 RT-PCR Test that provides the comprehensive reagents, components, materials required to simplify collection, transport, storage and detection of SARS-CoV-2. The solution allows biospecimens to be taken from the collection sites and transported to the hospitals and reference labs where viral RNA is extracted and detected by RT-PCR assays. Also on display at AACC 2021 was Fapon’s COVID-19 NAb Test Solution that provides alternative testing methods to gold standard live virus-based PRNT with high correlation in performances, solving the problems of requiring high laboratory safety level, long detection time and quantification.
In addition, Fapon highlighted its COVID-19 NAb (neutralizing antibody) Test Solution for Latex-Enhanced Immunoturbidimetry that provides alternative testing methods to gold standard live virus-based PRNT with high correlation in performances, solving the problems of requiring high laboratory safety level, long detection time and quantification. Fapon displayed its COVID-19 IgM & IgG Quality Control at the event. Fapon’s Anti-SARS-CoV-2 fully human RBD monoclonal antibody and N protein humanized monoclonal antibody outperform positive specimens by exhibiting higher stability, specificity and affinity. They are safe to handle with non-infectious, providing a valuable tool to reagent development, validation, and production.
Fapon also demonstrated the Shine i1000 Fully Automated CLIA Analyzer which has a throughput of up to 120 tests per hour and provides the first result in less than 15 minutes. It combines incubation, washing and detection in an all-in-one innovative design and its small size with a weight of less than 38 kg makes it ideal for different settings.
Related Links:
Fapon Biotech Inc.
Latest AACC 2021 News
- Study Showing Differing COVID-19 Antibody Profiles Among Vaccinated and Naturally Infected Individuals Presented at AACC 2021
- Study Reveals Varying Antibody Responses and Adverse Reactions Among Recipients of Different COVID-19 Vaccines
- Novel Study on Performance of Coronavirus Tests in Children Presented at 2021 AACC Annual Scientific Meeting
- New Rapid Test That Identifies Deteriorating COVID-19 Patients with Greater Accuracy than Existing Tests Presented at AACC 2021
- New Blood Test for Occupational Stress Identifies Healthcare Professionals Burned out from COVID-19 Pandemic
- New Non-Invasive Saliva Test for Early and Accurate Detection of Prostate Cancer Presented at AACC 2021
- New Non-Invasive Blood Test for Colon Cancer Presented at 2021 AACC Annual Scientific Meeting
- Study Establishing Accurate Reference Intervals for Pregnant Patients Presented at AACC 2021
- New Test that Measures Antibodies in Girls Who Have Received HPV Vaccine Presented at AACC 2021
- Novel Insights on COVID-19 Vaccines and Virus Evolution, AI in the Clinic, and Miniaturization of Diagnostic Platforms Explored at AACC 2021
- Seegene Unveils New STARlet-AIOS All-in-One Solution for All Molecular Testing at AACC 2021
- Group K Diagnostics Demonstrates KromaHealth Kit that Enables Lab-Quality Results at Point-of-Care
- NGeneBio Showcases NGS-Based Oncology/Genetic Diseases Kits and NGenePlex nCoV qRT-PCR Kit Against COVID-19
- Visby Medical Presents New Portable PCR COVID-19 Test Kit at 2021 AACC Annual Scientific Meeting & Clinical Lab Expo
- Fluxergy Introduces First-of-Its-Kind Multi-Modal Laboratory Platform That Diagnoses COVID-19 On-Site in 60 Minutes
- Mammoth Biosciences Presents AACC 2021 Disruptive Technology Award Finalist CRISPR-Based Detection Platform